KR20190008206A - 암 치료를 위한 병용요법 - Google Patents

암 치료를 위한 병용요법 Download PDF

Info

Publication number
KR20190008206A
KR20190008206A KR1020187032029A KR20187032029A KR20190008206A KR 20190008206 A KR20190008206 A KR 20190008206A KR 1020187032029 A KR1020187032029 A KR 1020187032029A KR 20187032029 A KR20187032029 A KR 20187032029A KR 20190008206 A KR20190008206 A KR 20190008206A
Authority
KR
South Korea
Prior art keywords
bchl
mdsc
pdt
vtp
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020187032029A
Other languages
English (en)
Korean (ko)
Inventor
아비그도르 셸츠
요람 살로몬
리락흐 아게미
레이첼 하므리
디나 프레이즈
광희 김
조나단 콜먼
Original Assignee
예다 리서치 앤드 디벨럽먼트 캄파니 리미티드
메모리얼 슬로안 케터링 캔서 센터
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드, 메모리얼 슬로안 케터링 캔서 센터 filed Critical 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드
Priority to KR1020227034306A priority Critical patent/KR20220139445A/ko
Publication of KR20190008206A publication Critical patent/KR20190008206A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020187032029A 2016-04-10 2017-04-10 암 치료를 위한 병용요법 Abandoned KR20190008206A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227034306A KR20220139445A (ko) 2016-04-10 2017-04-10 암 치료를 위한 병용 요법

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662320549P 2016-04-10 2016-04-10
US62/320,549 2016-04-10
PCT/IL2017/050440 WO2017179053A1 (en) 2016-04-10 2017-04-10 Combinational therapies for treatment of cancer comprising a bacteriochlorophyll derivative

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227034306A Division KR20220139445A (ko) 2016-04-10 2017-04-10 암 치료를 위한 병용 요법

Publications (1)

Publication Number Publication Date
KR20190008206A true KR20190008206A (ko) 2019-01-23

Family

ID=58794130

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187032029A Abandoned KR20190008206A (ko) 2016-04-10 2017-04-10 암 치료를 위한 병용요법
KR1020227034306A Abandoned KR20220139445A (ko) 2016-04-10 2017-04-10 암 치료를 위한 병용 요법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020227034306A Abandoned KR20220139445A (ko) 2016-04-10 2017-04-10 암 치료를 위한 병용 요법

Country Status (14)

Country Link
US (2) US11278555B2 (https=)
EP (1) EP3442582A1 (https=)
JP (2) JP2019510807A (https=)
KR (2) KR20190008206A (https=)
CN (2) CN118304400A (https=)
AU (2) AU2017250732B2 (https=)
BR (1) BR112018070847A2 (https=)
CA (1) CA3020067A1 (https=)
IL (1) IL262191B2 (https=)
MX (2) MX390751B (https=)
RU (2) RU2021110230A (https=)
SG (1) SG11201808849TA (https=)
WO (1) WO2017179053A1 (https=)
ZA (1) ZA201807187B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10107240B2 (en) 2014-04-04 2018-10-23 Dayco Ip Holdings, Llc Check valves and Venturi devices having the same
CN106458190B (zh) 2014-05-30 2019-12-06 戴科知识产权控股有限责任公司 具有喷射器、气动控制阀和可选择的吸气器的真空创建系统
EP3723785A1 (en) * 2017-12-17 2020-10-21 Yeda Research and Development Co. Ltd Cop9 signalosome (csn) complex modulators and uses thereof
WO2022149934A1 (ko) * 2021-01-08 2022-07-14 가톨릭대학교 산학협력단 암세포의 항암 면역치료를 위한 항체-폴리에틸렌글리콜-광감각제 접합체

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE347554T1 (de) 1998-12-09 2006-12-15 Yeda Res & Dev Palladiumsubstituierte bakteriochlorophyllderivate und deren verwendung
IL133253A0 (en) * 1999-12-01 2001-04-30 Yeda Res & Dev Chlorophyll and bacteriochlorophyll esters, their preparation and pharmaceutical compositions comprising them
IL152900A0 (en) * 2002-11-17 2003-06-24 Yeda Res & Dev Water-soluble bacteriochlorophyll derivatives and their pharmaceutical uses
PT2061512T (pt) 2006-08-23 2020-01-14 Yeda Res & Dev Conjugados de péptidos com rgd e fotossensibilizantes de (bacterio)clorofila e as suas utilizações
US8673270B2 (en) 2008-10-23 2014-03-18 Steba Biotech S.A. RGD-containing peptidomimetics and uses thereof
WO2012106343A2 (en) * 2011-02-01 2012-08-09 The Board Of Trustees Of The University Of Illinois Hdac inhibitors and therapeutic methods using the same
TWI442945B (zh) * 2011-05-18 2014-07-01 Univ Nat Taiwan 雙效微脂體用於治療的方法
WO2014141289A1 (en) * 2013-03-12 2014-09-18 Amrita Vishwa Vidyapeetham University Photo - chemo composition on the basis of microcapsules with a core -shell structure

Also Published As

Publication number Publication date
CA3020067A1 (en) 2017-10-19
US20220202838A1 (en) 2022-06-30
AU2017250732B2 (en) 2022-11-10
WO2017179053A1 (en) 2017-10-19
MX2018012392A (es) 2019-08-21
IL262191B2 (en) 2025-01-01
RU2747258C2 (ru) 2021-04-29
IL262191B1 (en) 2024-09-01
ZA201807187B (en) 2020-01-29
RU2018139523A (ru) 2020-05-15
US11278555B2 (en) 2022-03-22
US20190125769A1 (en) 2019-05-02
EP3442582A1 (en) 2019-02-20
SG11201808849TA (en) 2018-11-29
MX2022003190A (es) 2022-04-11
CN109862918A (zh) 2019-06-07
BR112018070847A2 (pt) 2019-02-05
RU2021110230A (ru) 2021-05-26
MX390751B (es) 2025-03-21
JP2022031823A (ja) 2022-02-22
AU2017250732A1 (en) 2018-11-15
IL262191A (en) 2018-11-29
CN118304400A (zh) 2024-07-09
JP2019510807A (ja) 2019-04-18
KR20220139445A (ko) 2022-10-14
AU2023200591A1 (en) 2023-03-09
RU2018139523A3 (https=) 2020-07-07

Similar Documents

Publication Publication Date Title
US20220202838A1 (en) Combinational therapies for treatment of cancer comprising a bacteriochlorophyll derivative
RU2723021C2 (ru) Применение плинабулина в комбинации с ингибиторами контрольной точки иммунного ответа
Wang et al. Molecular engineering of anti-PD-L1 peptide and photosensitizer for immune checkpoint blockade photodynamic-immunotherapy
EP2944323B1 (en) Agents for treating tumours, use and method thereof
Simonelli et al. Checkpoint inhibitors as treatment for malignant gliomas:“A long way to the top”
EP2234642B1 (en) Method of increasing immunological effect
KR20190096936A (ko) 암 치료를 위하여 tlr9 작용제를 사용한 면역 조정
Milling et al. Neoadjuvant STING activation, extended half-life IL2, and checkpoint blockade promote metastasis clearance via sustained NK-cell activation
Li et al. Combination treatment with immunogenic and anti-PD-L1 polymer-drug conjugates of advanced tumors in a transgenic MMTV-PyMT mouse model of breast cancer
US20200377596A1 (en) Dosing of bispecific t cell engager
Donahue et al. A pan inhibitor of DASH family enzymes induces immunogenic modulation and sensitizes murine and human carcinoma cells to antigen-specific cytotoxic T lymphocyte killing: implications for combination therapy with cancer vaccines
Chen et al. A rapid ex vivo co-culture of memory-like NK and activated T cells enhances anti-tumor response in gastric cancer.
EP4126051B1 (en) Reduced caloric intake and immunotherapy for the treatment of cancer
WO2023203561A1 (en) Apoptotic cell - check point inhibitor combination therapy
La Rosa et al. Comparative study of immune response to local tumor
Zhang et al. In situ therapeutic vaccines for leukemia by chemo-nanoadjuvant therapy
Metzler et al. Differential promotion of hematopoietic chimerism and inhibition of alloreactive T cell proliferation by combinations of anti-CD40Ligand, anti-LFA-1, everolimus, and deoxyspergualin
van Zandwijk et al. Cellular Immunotherapy and Locoregional Administration of CAR T-Cells in Malignant Pleural
US20200030375A1 (en) Therapy and methods of introducing immature dendritic cells and/or cytoxic t lymphocyte and anti pd-1 / pd-l1 antibody for treatment of tumors
Hamri Targeting the microenvironment of 4T1 tumors using RGD-conjugated bacteriochlorophylls as a theranostic tool
Bently et al. Melanoma Immunomodulation: A War of Attrition

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PC1901 Submission of document of abandonment after decision of registration

St.27 status event code: N-1-6-B10-B11-nap-PC1901